CTIS2024-514597-42-00招募中1 期
Combining anti-PD-L1 immune checkpoint inhibitor durvalumab with TLR-3 agonist rintatolimod in patients with metastatic pancreatic ductal adenocarcinoma for therapy efficacy. DURIPANC Study
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 43
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •Histologically or cytologically (Bethesda 5 or 6) confirmed metastatic pancreatic cancer, as indicated by a definite cytology/histology report., Adequate renal function (eGFR > 40 ml/min)., Adequate liver tests (bilirubin = 1.5 times normal; ALAT/ASAT = 5 times normal)., Adequate bone marrow function (WBC > 3.0 x 109/L, platelets > 75 x 109/L , absolute neutrophil count (ANC) =1.0 × 109 /L and hemoglobin > 5.6 mmol/L., Effective contraceptive methods., Patient must have a life expectancy of at least 12 weeks., Patient is willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations including follow up., Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol. Written informed consent and any locally required authorization (e.g., European Union Data Privacy Directive) obtained from the patient/legal representative prior to performing any protocol-related procedures, including screening evaluations., Stable disease according to RECIST criteria version 1.1 after at least 8 cycles of chemotherapy (FOLFIRINOX)., Inclusion = 6 weeks after stopping FOLFIRINOX., An accessible metastatic lesion for histological tissue collection., SIII<900 (Systemic Immune-Inflammation Index = ((absolute neutrophil count * platelet count) / absolute lymphocyte count))., CA 19.9 <1000kU/L, Age = 18 years at time of study entry., Body weight >30 kg., WHO performance status of 0-1.
排除标准
- •Child-Pugh Classification grade B/C., Prior randomisation or treatment in a previous durvalumab clinical study regardless of treatment arm assignment., Participation in another clinical study with an investigational product during the last 3 months., Concurrent enrolment in another clinical study, unless it is an observational (non-interventional) clinical study or during the follow-up period of an interventional study., Receipt of the last dose of anticancer therapy (chemotherapy, immunotherapy, endocrine therapy, targeted therapy, biologic therapy, tumor embolization, monoclonal antibodies) =28 days prior to the first dose of study drug If sufficient wash-out time has not occurred due to the schedule or PK properties of an agent, a longer wash-out period will be required, as agreed by AstraZeneca and the investigator., Any unresolved toxicity NCI CTCAE Grade =2 from previous anticancer therapy with the exception of alopecia, vitiligo, and the laboratory values defined in the inclusion criteria. oPatients with Grade =2 neuropathy will be evaluated on a case-by-case basis after consultation with the Study Physician. oPatients with irreversible toxicity not reasonably expected to be exacerbated by treatment with durvalumab may be included only after consultation with the Study Physician., Any concurrent chemotherapy, IP, biologic, or hormonal therapy for cancer treatment. Concurrent use of hormonal therapy for non-cancer-related conditions (e.g., hormone replacement therapy) is acceptable., Radiotherapy treatment to more than 30% of the bone marrow or with a wide field of radiation within 4 weeks of the first dose of study drug., Major surgical procedure (as defined by the Investigator) within 28 days prior to the first dose of IP. Note: Local surgery of isolated lesions for palliative intent is acceptable., History of allogenic organ transplantation., Uncontrolled intercurrent illness, including but not limited to, ongoing or active infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, cardiac arrhythmia, interstitial lung disease, serious chronic gastrointestinal conditions associated with diarrhea, or psychiatric illness/social situations that would limit compliance with study requirement, substantially increase risk of incurring AEs or compromise the ability of the patient to give written informed consent., Current treatment with immunotherapeutic drugs., History of leptomeningeal carcinomatosis., Brain metastases or spinal cord compression. Patients with suspected brain metastases at screening should have an MRI (preferred) or CT each preferably with IV contrast of the brain prior to study entry to rule out the presence of brain metastasis., Mean QT interval corrected for heart rate using Fridericia's formula (QTcF) =470 ms., Known active hepatitis infection, positive hepatitis C virus (HCV) antibody, hepatitis B virus (HBV) surface antigen (HBsAg) or HBV core antibody (anti-HBc), at screening. Participants with a past or resolved HBV infection (defined as the presence of anti HBc and absence of HBsAg) are eligible. Participants positive for HCV antibody are eligible only if polymerase chain reaction is negative for HCV RNA. Adjust wording as necessary and consider evaluating at screening for studies with known hepatotoxicity or other relevant requirements., Known to have tested positive for human immunodeficiency virus (HIV) (positive HIV 1/2 antibodies) or active tuberculosis infe
研究者
相似试验
招募中
不适用
Combining anti-PD-L1 immune checkpoint inhibitor durvalumab with TLR-3 agonist rintatolimod in patients with metastatic pancreatic ductal adenocarcinoma for therapy efficacy. DURIPANC study.metastatic pancreatic cancermetastatic pancreatic ductal adenocarcinoma1001567410017991NL-OMON56232Erasmus MC, Universitair Medisch Centrum Rotterdam43
已完成
不适用
Combination therapy of immuno checkpoint inhibitors and radiosensitization treatment for metastatic melanomaJPRN-UMIN000026925Kochi University, Kochi Medical School5
尚未招募
不适用
Administration of immune checkpoint inhibitors through an elastomeric pump. A patient preference study and cost analysis.Solid tumors for which nivolumab or pembrolizumab monotherapy has an EMA approved indication. This includes (but is not limited to) melanoma, renal-cell cancer, NSCLC and head and neck cancer.NL-OMON25676Erasmus MC390
进行中（未招募）
1 期
Patient preference for administration of cancer immunotherapy via an elastomeric pump. A patient preference study and an economic analysis.Solid tumors for which nivolumab or pembrolizumab monotherapy is an EMA approved indication. This includes (but is not limited to) melanoma, renal-cell cancer, NSCLC and head and neck cancer.EUCTR2021-000058-24-NLErasmus MC Cancer Institute390
招募中
4 期
Administration of immune checkpoint inhibitors through an elastomeric pump. A patient preference study and cost analysis.NSCLC and head and neck cancerrenal-cell cancerSolid or hematological tumors for which Nivolumab or Pembrolizumab monotherapy have an EMA approved indication. This includes (but is not limited to) melanomaVarious forms of cancer for which Nivolumab or Pembrolizumab monotherapy are prescribed as treatment10027656NL-OMON54425Erasmus MC, Universitair Medisch Centrum Rotterdam390